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fiEAR IN CARDIOLOGY SERIES2343The Year in Epidemiology, Health Services Research, and Outcomes Researchark A. Hlatky, Paul Heidenreich
n this paper, Hlatky and Heidenreich summarize a few of the highlights in the fields of
pidemiology, health services research, and outcomes research published between April 2008
nd June 2009. Included are synopses of a range of articles, from those that link obesity to
ardiac events, to the cost-effectiveness of percutaneous coronary intervention for patients with
table angina, to understanding and reducing the effects of racial disparities in cardiac care.IPID-LOWERING AND TOTAL CARDIOVASCULAR BURDEN
2353enefits of Intensive Lipid Lowering Extend
Beyond Reductions in the Time to First Event CMEatti J. Tikkanen, Michael Szarek, Rana Fayyad, Ingar Holme, Nilo B. Cater, Ole Faergeman,
ohn J. P. Kastelein, Anders G. Olsson, Mogens Lytken Larsen, Christina Lindahl, Terje R. Pedersen,
or the IDEAL Investigators
his post-hoc analysis of the IDEAL (Incremental Decrease in End Points Through
ggressive Lipid Lowering) trial by Tikkanen and colleagues compared the efficacy of high-
ose atorvastatin and usual-dose simvastatin for the prevention of all cardiovascular (CV)
vents, rather than just the first event that was the primary end point of the trial. The authors
sed the Wei, Lin, and Weissfeld method, which may be more informative because during
he course of long-term trials, a large number of events may occur subsequent to the first
vent. The relative risk of a first CV event in those treated with atorvastatin was reduced by
7%, of a second by 24%, of a third by 19%, of a fourth by 24%, and of a fifth by 28%.
hese results indicate that the benefits of intensive statin therapy continue beyond the
rst event.(continued on page A-21)
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EIPID-LOWERING AND TOTAL CARDIOVASCULAR BURDEN
2358eduction in First and Subsequent Events
With Atorvastatin in the PROVE IT–TIMI 22 Trialabina A. Murphy, Christopher P. Cannon, Stephen D. Wiviott, Carolyn H. McCabe, Eugene Braunwald
he PROVE IT–TIMI 22 (Pravastatin and Atorvastatin in Evaluation and Infection
herapy–Thrombolysis In Myocardial Infarction 22) trial showed that atorvastatin 80 mg
educed the incidence of a first primary end point by 16% compared with pravastatin 40 mg
n subjects presenting with an acute coronary syndrome. Murphy and colleagues reanalyzed
he data to determine if there were similar reductions in recurrent and total events throughout
he duration of the study using the Poisson regression analysis. Using the standard statistical
echnique of counting first events, atorvastatin prevented only 73 events. However, subsequent
vents were also reduced with atorvastatin 80 mg, resulting in 138 fewer total primary events
uring the study (rate ratio: 0.85). Based on the primary end point results, the number
eeded to treat is 26; however, the number needed to prevent 1 event is much lower at
4 when all events are considered.ditorial Comment: Steven E. Nissen, p. 2363ARDIOVASCULAR RISK AND MENOPAUSE2366Significant Increase in Cardiac Risk Factors at Time of Menopausearen A. Matthews, Sybil L. Crawford, Claudia U. Chae, Susan A. Everson-Rose, Mary Fran Sowers,
arbara Sternfeld, Kim Sutton-Tyrrell
his prospective study by Matthews and colleagues sought to determine whether changes in
raditional and novel coronary heart disease (CHD) risk factors can be temporally related to
enopause or are gradual changes associated with aging. SWAN (Study of Women’s Health
cross the Nation) is a prospective study of the menopausal transition in 3,302 women of
ultiple ethnicities. Women were surveyed annually, were asked about their menstrual cycles,
nd had their CHD risk factors measured. Total cholesterol, low-density lipoprotein
holesterol (LDL-C), and apolipoprotein-B demonstrated substantial increases within the
-year interval before and after the final menstrual period (FMP), consistent with menopause-
nduced changes. Other risk factors, including other lipoproteins, glucose, insulin, blood
ressure, fibrinogen, and C-reactive protein, changed gradually indicative of chronological
ging. This suggests that women experience a rise in apolipoprotein-B–containing lipids
t the time of their FMP.
ditorial Comment: Vera Bittner, p. 2374(continued on page A-29)
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sARDIOVASCULAR RISK AND DIET AND SMOKING2376Effect of Weight Loss and Regain on Cardiac Structure and Functionisa de las Fuentes, Alan D. Waggoner, B. Selma Mohammed, Richard I. Stein, Bernard V. Miller III,
ary D. Foster, Holly Wyatt, Samuel Klein, Victor G. Davila-Roman
e las Fuentes and colleagues performed a 2-year dietary intervention study to evaluate the
ffects of moderate weight reduction and subsequent partial weight regain on cardiovascular
tructure and function. In the 47 subjects who completed the entire 2-year follow-up, average
eight loss was 7%, 9%, 8%, and 4% at 3, 6, 12, and 24 months, respectively. There were
ignificant improvements and strong correlations between the change in weight and changes
n left ventricular mass, carotid intima-media thickness, and left ventricular diastolic (E’) and
ystolic (S’) function. Partial weight regain diminished the beneficial effects of weight loss.
iet-induced moderate weight loss in obese subjects is associated with beneficial changes in
ardiovascular structure and function.ARDIOVASCULAR RISK AND DIET AND SMOKING2382Benefits to Quitting, Even Reducing, Cigarette Useariv Gerber, Laura J. Rosen, Uri Goldbourt, Yael Benyamini, Yaacov Drory, for the Israel Study Group
n First Acute Myocardial Infarction
erber and colleagues compared long-term survival after acute myocardial infarction (AMI)
f never-smokers, pre-AMI quitters, post-AMI quitters, and persistent smokers, and assessed
hether cigarette reduction among persistent smokers is associated with lower mortality. Over
,500 subjects age 65 years who survived an AMI in 1992 to 1993 were followed through
005. The multivariable-adjusted hazard ratios (HRs) for mortality were 0.57 for never-
mokers, 0.50 for pre-AMI quitters, and 0.63 for post-AMI quitters, compared with
ersistent smokers. Among persistent smokers, each reduction of 5 cigarettes smoked daily
as associated with an 18% decline in mortality risk. Smoking cessation either before or after
MI is associated with improved survival, as is reducing the daily number of cigarettes
moked.(continued on page A-30)
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EREATMENT IMPLICATIONS OF THE JUPITER TRIAL
2388eanalysis of ARIC Data Confirms Elevated
Cardiac Risk in Subjects With Elevated CRP, Low LDL-Cric Y. Yang, Vijay Nambi, Zhengzheng Tang, Salim S. Virani, Eric Boerwinkle, Ron C. Hoogeveen,
rad C. Astor, Thomas H. Mosley, Josef Coresh, Lloyd Chambless, Christie M. Ballantyne
osuvastatin therapy was shown to reduce cardiovascular disease (CVD) events in men and
omen (50 and 60 years of age, respectively) with low-density lipoprotein cholesterol
LDL-C) 130 mg/dl and high-sensitivity C-reactive protein (hs-CRP) 2.0 mg/l without
nown CVD in the JUPITER (Justification for the Use of statins in Prevention: an
ntervention Trial Evaluating Rosuvastatin) trial. Yang and colleagues used data from the
RIC (Atherosclerosis Risk in Communities) study to estimate what percentage of
he population would meet eligibility criteria as defined by the JUPITER trial and the
ardiovascular risk in these patients. Of the nearly 9,000 appropriately-aged participants
n the ARIC trial, 18% were “JUPITER-eligible.” These subjects had an absolute CVD
isk of 10.9% and an event rate of 1.57% per year, which was similar to the 1.36% per
ear in the placebo arm of the JUPITER trial. If JUPITER hazard ratios were applied to
his group, the number needed to treat to prevent 1 CVD event would be 38 over 5 years
nd 26 over 6.9 years.THEROSCLEROSIS MARKERS AND PHYSICAL ACTIVITY IN CHILDREN2396Increased Physical Activity Improves BP in Pre-Pubertal Obese Childrenathalie J. Farpour-Lambert, Yacine Aggoun, Laetitia M. Marchand, Xavier E. Martin,
rançois R. Herrmann, Maurice Beghetti
arpour-Lambert and colleagues sought to determine the effects of physical activity on
ystemic blood pressure (BP) and early markers of atherosclerosis in pre-pubertal obese
hildren. Subjects were randomized to 3 months of supervised, thrice-weekly exercise or to no
ntervention; all subjects then participated in supervised activity for an additional 3 months.
ompared to lean control children, obese children had higher BP, arterial stiffness, insulin
esistance indexes, and C-reactive protein levels and lower flow-mediated dilation, maximal
xygen consumption, and physical activity than lean subjects. After 3 months of exercise,
4-h systolic BP decreased by 7 mm Hg, and improvements were also seen in arterial stiffness
nd intima-media thickness. A regular physical activity program reduces BP and arterial
tiffness and delays arterial wall remodeling in pre-pubertal obese children.
ditorial Comment: David S. Celermajer, p. 2407(continued on page A-34)
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wFFECTIVENESS OF CARDIAC IMAGING2409Cost-Effectiveness and Clinical Utility of CCTA in Patients With Chest Painoseph A. Ladapo, Farouc A. Jaffer, Udo Hoffmann, Carey C. Thomson, Fabian Bamberg, William Dec,
avid M. Cutler, Milton C. Weinstein, G. Scott Gazelle
adapo and colleagues used published data to develop a computer simulation to predict
linical outcomes, health care costs, and cost-effectiveness of coronary computed tomography
ngiography (CCTA) compared with conventional testing modalities for a target population
f 55-year-old patients with stable chest pain. All diagnostic strategies yielded similar health
utcomes, but performing CCTA, with or without stress testing or performing stress single-
hoton emission computed tomography, marginally minimized adverse events and maximized
ongevity and quality-adjusted life-years (QALYs). CCTA raised overall costs, partly through
he follow-up of incidental findings. When performed with stress testing, its incremental
ost-effectiveness ratio ranged from $26,200 per QALY in men to $35,000 per QALY in
omen. These results suggest that CCTA is comparable to other diagnostic studies, but large
andomized trials are needed.EWS FROM THE NCDR2423Significant Improvements in Door-to-Balloon Timelizabeth H. Bradley, Brahmajee K. Nallamothu, Jeph Herrin, Henry H. Ting, Amy F. Stern,
ngrid M. Nembhard, Christina T. Yuan, Jeremy C. Green, Eva Kline-Rogers, Yongfei Wang, Jeptha P. Curtis,
ashonna R. Webster, Frederick A. Masoudi, Gregg C. Fonarow, John E. Brush, Jr, Harlan M. Krumholz
he objective of this report from the National Cardiovascular Data Registry was to determine
f enrollment in the Door-to-Balloon (D2B) Alliance was associated with decreased D2B
ime for patients undergoing primary percutaneous coronary intervention (PPCI). By March
008, 75% of patients had D2B times 90 min, compared with only about one-half of
atients 3 years earlier. Patients treated in hospitals enrolled in the D2B Alliance were
ignificantly more likely to have D2B times 90 min than were those treated in nonenrolled
ospitals. The authors conclude that the D2B Alliance reached its goal of 75% of patients
ith ST-segment elevation myocardial infarction having D2B times within 90 min.(continued on page A-35)
DECEMBER 15/22, 2009 (continued) A-35IINTERVENTIONAL CARDIOLOGYK
H
G
J
T
(
d
p
E
h
e
a
3
d
f
p
P
S
C
H
B
(
r
r
l
i
s
o
iNTERVENTIONAL CARDIOLOGY2430Impella 2.5 Device May Be Useful for Supporting High-Risk PCIrischan D. Sjauw, Thomas Konorza, Raimund Erbel, Paolo L. Danna, Maurizio Viecca,
ans-Heinrich Minden, Christian Butter, Thomas Engstrøm, Christian Hassager, Francisco P. Machado,
iovanni Pedrazzini, Daniel R. Wagner, Rainer Schamberger, Sebastian Kerber, Detlef G. Mathey,
oachim Schofer, Annemarie E. Engstrom, Jose P. S. Henriques
his retrospective multicenter registry evaluated the safety and feasibility of left ventricular
LV) support with the Impella 2.5 device (Abiomed Europe GmbH, Aachen, Germany)
uring high-risk percutaneous coronary intervention (PCI). The Impella 2.5 device is a
ercutaneous implantable LV assist device that can be placed retrogradely into the LV. The
uropella registry included 144 consecutive patients in whom the device was used to support
igh-risk PCI. One-half of patients had a previous myocardial infarction, one-half had an LV
jection fraction 30%, almost one-half had been refused for coronary artery bypass grafting,
nd one-half were undergoing left main PCI. The mean assist time was 1 h 28 min, with a
0-day mortality of 5.5% and only 1 stroke within 30 days of the procedure. There were no
evice-related complications except for access site issues. This registry data supports the safety,
easibility, and potential usefulness of hemodynamic support with the Impella 2.5 device in
atients undergoing high-risk PCI.PRE-CLINICAL RESEARCH RE-CLINICAL RESEARCH2435Oral Everolimus Ameliorates Post-MI Remodelingebastian J. Buss, Sebastian Muenz, Johannes H. Riffel, Pratima Malekar, Marco Hagenmueller,
eline S. Weiss, Florian Bea, Raffi Bekeredjian, Martina Schinke-Braun, Seigo Izumo,
ugo A. Katus, Stefan E. Hardt
uss and colleagues investigated whether inhibition of “mammalian target of rapamycin”
mTOR) could attenuate left ventricular remodeling following myocardial infarction (MI) in a
at model because mTOR-dependent signaling mechanisms appear to be involved in the
emodeling processes. Everolimus (RAD) treatment was initiated after induction of MI by
eft anterior descending coronary artery ligation. After 28 days, RAD-treated animals had
mproved left ventricular function and smaller left ventricular volumes. By histology, infarct
ize was significantly reduced, and there was decreased proteasome activity in the border zone
f the infarcted myocardium. Inhibition of mTOR is a potential therapeutic strategy to limit
nfarct size and to attenuate adverse left ventricular remodeling following MI.
